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Recent WHO classification for combined hepatocellular–cholangiocarcinoma and recognized 
stem cell subtypes has increased attention to such tumors; however, the resulting burst of 
reporting and research indicates that this classification, while provocative, is incomplete for 
description of the full array of primary liver carcinomas with biphenotypic (hepatobiliary) 
differentiation. We review the history of such lesions and consider the wider array of such 
tumors previously described. Mixed hepatobiliary phenotypes and immunophenotypes 
are found in individual tumors at the tissue level – with architectural and cytologic features 
Practice points
 ●  Diversity is increasingly recognized in primary liver carcinomas (PLCs), changing 
the dichotomy of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) as 
distinctly separate tumors in all situations.
 ●  PLCs with mixed hepatobiliary differentiation have been described in the 
literature for over 100 years, first by histopathology, then with the addition of 
immunohistochemistry to identify markers of biliary and/or progenitor cell or stem 
cell differentiation. The presence of such markers is commonly associated with a 
worse prognosis.
 ●  PLCs may have mixed ‘hepatobiliary’ features (i.e., biphenotypic [hepatobiliary] PLC) 
at many levels: at the gross tissue level, at the microscopic (cellular) morphologic 
level or by immunophenotypes. The latter group includes the ‘pure’ HCC with 
biliary findings by immunophenotype, pure CC with hepatocytic findings by 
immunophenotype, cholangiolocellular carcinomas and PLC without typical 
morphology but with mixed hepatobiliary immunophenotype.
 ●  Classification of biphenotypic (hepatobiliary) PLC must always begin with the 
light microscopic morphologic assessments; immunophenotyping is reserved as a 
secondary means of identification.
 ●  Molecular studies to date of microdissected biphenotypic (hepatobiliary) 
PLCs have shown surprisingly more homogeneity than the histologic and/or 
immunohistochemical phenotypes, and are closer to CC than to HCC.
 ●  Many clinical, pathologic and molecular questions remain unanswered regarding 
these complex tumors; the first task to promote studies that can answer these 
questions is to establish consistent consensus terminology and method(s) for analysis.
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Traditional teaching has it that there are two 
interconnected, but separate epithelial com-
partments in the liver: hepatocytes and cholan-
giocytes. Traditional teaching follows then that 
primary liver carcinomas (PLCs) reflect this 
dichotomy: hepatocellular carcinoma (HCC), 
and cholangiocarcinoma (CC), each with vari-
ants. We now know that hepatobiliary lineages 
are more flexible as displayed most prominently 
by ductular reactions that are present in liver 
injury of all forms in varying degrees. Just as 
these reactive lesions display a range of epithelial 
phenotypes between the hepatocytic and chol-
angiocytic differentiation, likewise, increasingly, 
similar diversity is being recognized in PLCs.
The other relatively uncommon kinds of pri-
mary liver cancers (e.g., mucinous cystic neo-
plasms, biliary intraductal papillary neoplasms) 
and special types of HCC (e.g., fibrolamellar 
carcinoma) have established diagnostic crite-
ria that are readily applied. However, increas-
ingly commonly, new forms of PLC are being 
seen worldwide: tumors of mixed hepatobiliary 
phenotypes and immunoexpression that are 
presenting with a wide range of clinical, imag-
ing and histopathologic complexities and, thus 
confusion. These include not only the most well-
described ‘combined hepatocellular–cholangio-
carcinoma’ (cHCC-CC), but also several variants 
– including those with ‘stem cell features.’
In this review, we discuss and show exam-
ples of PLC with such mixed hepatobiliary 
features and explore many of the clinicopatho-
logic questions they raise. Some of these tumors 
may indeed be new forms of PLC, related to 
the changing incidences of important, prema-
lignant conditions; they may be a reflection of 
newly recognized PLC variants either because 
of detailed hepatobiliary immunophenotyping 
not previously available to pathologists or the 
newly sensitive imaging techniques in practice 
today. Though there are few absolute answers 
for the questions that recognition of these 
tumors raise, we take this opportunity to put 
the discussion first into historical context, then 
to detail currently published diagnostic cat-
egories, to summarize existing molecular data 
concerning the lesions and finally to point to 
diagnostic approaches needed to further refine 
our understanding of these tumors.
A final note concerns terminology: there is 
currently no accepted consensus terminology for 
these tumors. Indeed, expert liver pathologists in 
the field are not in full agreement. Some favor 
the broad term ‘biphenotypic PLC’; others argue 
that this may be imprecise, since there may be 
many different forms of biphenotypia outside 
the theme of this paper (e.g., HCC squamous, 
adenosquamous, sarcomatoid HCC). On the 
other hand ‘mixed hepatobiliary carcinomas’ is 
preferred by some. The argument against this 
term is the implication of specific differentiation 
when in fact, some of these tumors may appear 
to be monomorphic by light microscopy, and 
only the application of immunohistochemistry 
(IHC) highlights the true biphenotypic expres-
sion of the cells within the tumor. For this 
review, we chose to observe the inelegant, albeit 
unsimplified convention of this paper’s title: 
biphenotypic (hepatobiliary) PLC, abbreviated 
to b(HB)-PLC.
An established nomenclature – that is scien-
tifically valid and clinically meaningful – still 
needs time to undergo community wide dis-
cussion, consensus building, understanding 
of pathophysiology and acceptance over the 
coming years.
Historical overview
During the last three decades, many publica-
tions, partly reviewed in Table 1, have reported 
and analyzed liver tumors that are clearly to be 
considered b(HB)-PLC. The presence of tumors 
displaying features of both hepatocellular and 
biliary origin was described for the first time by 
HG Wells more than 100 years ago [1] although 
Allen and Lisa’s description of five cases is often 
cited as the first [2]. In their series, the tumors 
were noted as separate or contiguous tumors 
with differentiation typical for HCC and CC. 
Further description showed two separate tumors 
arising distantly in the same liver, two contigu-
ous tumors intermingling at their borders and 
one single mass showing both hepatocellular 
and biliary features. In the milestone paper of 
Edmondson and Steiner published in 1954 [3], 
4% of their entire series of PLC showed both 
hepatocellular and biliary differentiation. Their 
recommendation for terminology was ‘hepato-
biliary cancers,’ but also recommended that they 
KeywoRds   
• cholangiocarcinoma 
• cholangiolocellular 





• liver progenitor cell 
• liver stem cell • mixed 
hepatobiliary carcinoma 
• primary liver carcinoma 
• stem cell tumor • stemness
supportive of both differentiation states – and at the cellular level, with individual cells that 
display cytology of one cell type, but immunophenotypically showing mixed expression. 
Pathobiologic and clinical questions to be answered by future research are suggested.
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Table 1. Literature review on biphenotypic (hepatobiliary) primary liver carcinomas.
Study (year), (n, if given) Proposed nomenclature New concept proposed Ref.
Wells (1903), (n = 1) Primary carcinoma of the liver First description [1]
Allen and Lisa (1949), (n = 5)
 




 ● Two distinct tumors in different parts of liver
 ● Two separate tumors adjacent and intermingling
 ● One tumor with intimately associated cellular components due 
to origin from same focus
[2]
 
Steiner et al. (1959), (n = 11) Cholangiolocarcinoma First description [4]






 ● Collision: separate HCC and CC in same liver
 ● Transitional: single tumor with features of both HCC and CC
 ● Fibrolamellar: primarily FL-HCC but with mucin-producing foci
[5]
 
Maeda et al. (1995), (n = 36) Combined HCC-CC First survival rates after resection: combined HCC-CC has worse 
outcomes
[6]
Wu et al. (1996), (n = 290 
HCC); Wu et al. (1999), (n = 64 
from the previous series)
HCC with dual (hepatocellular/
biliary) phenotype
Marked difference in survival: shorter if biliary features; 
expression of K14 means either derived from progenitor cells or 
regressed to the bipotential progenitor cell phenotype during 
carcinogenesis
[7,8]
Robrechts et al. (1998), (n=1)  Intermediate cell tumor; dense 
stroma
Possibly derived from progenitor cell; by light and electron 
microscopy, expression of hepatocyte and biliary keratins
[9]
Tickoo et al. (2002), (n = 27) Combined HCC-CC All had ‘transitional’ areas; utilized albumin ISH to prove HC 
differentiation; 96% showed both ISH and biliary keratins = 
‘biphenotypic’ differentiation
[10]
Theise et al. (2003), (n = 4) Combined HCC-CC Tumors contained undifferentiated cells with morphological and 
immunohistochemical features of hepatic progenitor cells
[11]
Yano et al. (2003), (n = 26) Combined HCC-CC More similar to HCC, than to CC clinically except more advanced 
disease stage; survival worse than HCC and CC
[12]
Kim et al. (2004), (n = 54) Primary hepatic carcinoma 
of intermediate (hepatocyte-
cholangiocyte) phenotype
Morphologically intermediate can arise from progenitor cells [13,14]
 
Kim et al. (2011) HCC only: impact of stemness 
features
K19 correlated with clinicopathologic features of tumor 
aggressiveness, more invasive characteristics, compared with 
K19-negative HCCs through the upregulation of EMT-associated 
genes
Cazals-Hatem et al. (2004), 
(n = 9)
Combined HCC-CC Closer in mutations to CC than to HCC [15]
Durnez et al. (2006), (n = 109) HCC only: impact of progenitor 
cell component
>5% K19 positivity = higher recurrence rate and worse prognosis [16]
Aishima et al. (2006), (n = 40) Combined HCC-CC Four subtypes based on the amount of CC component: outcomes 
relies on ≥60% CC component and/or sarcomatous component
[17,18]
Aishima et al. (2007), (n = 35) Combined HCC-CC HCC smaller than 3 cm in diameter can have biliary differentiation 
and prognosis is worse
 
Komuta et al. (2008), (n = 30) Cholangiolocellular carcinoma Investigated relationship to HPCs, HCC and CC: CLC and K19 HCC 
have high homology: both are likely progenitor cell derived 
association with HCC and sometimes with CC
[19]
WHO (2010) Combined HCC-CC Unequivocal components of both HCC and CC in same 
tumor; does not include two separate tumors either in same 
liver or simply adjacent to each other; four types: classic or 
stem cell features (three subtypes: typical, intermediate and 
cholangiocellular)
[20]
?: Questioned if tumor was of progenitor cell origin; CC: Cholangiocarcinoma; CLC: Cholangiolocellular carcinoma; HCC: Hepatocellular carcinoma;  
HCC-CC: Hepatocellular–cholangiocarcinoma; HPC: Hepatic progenitor cell; IHC: Immunohistochemistry; ISH: In situ hybridization; PLC: Primary liver carcinoma.
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be contained within the group of HCC as they 
were mostly observed in men on a cirrhotic back-
ground, as with classical HCC. This combined 
type of cancer was considered by the authors 
as ‘a problem difficult to solve at the present’, a 
relevant opinion today, 60 years later.
The first part of the 20th century was the era 
of histopathology alone and extensive descrip-
tions of the histological and cytological char-
acteristics of b(HB)-PLC were supported by 
numerous photomicrographic figures. Since 
that time, a diagnosis of b(HB)-PLC requires 
the unequivocal histological presence of both 
hepatocellular and cholangiocellular elements 
within the same tumor, as stated by the 2000 
WHO classification of the digestive tumors [28].
With the developments of IHC new con-
cepts emerged. In 1985, Goodman [5] reported 
the experience of the Armed Forces Institute of 
Pathology with 24 cases and classified them in 
three categories, only slightly modified from 
those of Allen and Lisa. The first was termed 
the ‘collision type,’ corresponding to the 
coincidental occurrence of both HCC and CC, 
distinctly separate, in the same liver. The second 
was the ‘transitional type,’ with intermediate 
differentiation and areas of transition between 
HCC and CC. The third was the ‘fibrolamel-
lar type,’ resembling fibrolamellar HCC, but 
containing pseudoglands producing mucin. 
α-fetoprotein, a marker of hepatocytic differ-
entiation, and staining for ‘keratins’ (polyclonal 
antikeratin antibodies unspecified in the study, 
but probably against those typically expressed 
in cholangiocytes alone, such as K7 and K19), 
markers of cholangiocytic differentiation, were 
both found to be expressed in these mixed 
tumors collectively termed ‘combined hepato-
cellular cholangiocarcinomas’ according to the 
authors.
IHC was subsequently used more and more 
in order not only to help in diagnosing PLCs 
of all kinds and to distinguish between them 
and poorly differentiated metastatic carcino-
mas, but also to assess their origin(s), and to 
study and subtype HCC and, to a lesser extent, 
Study (year), (n, if given) Proposed nomenclature New concept proposed Ref.








 ● HCC with stem/progenitor cell 
immunophenotype
 ● Mixed hepatobiliary, classical 
type
 ● Mixed hepatobiliary with stem/
progenitory phenotype and 
immunophenotype
All are subtypes of ‘progressed HCC’
 ● >5% of tumor cells express stem/progenitor IHC markers: K19, 
EpCAM, CD133, etc.; not recognizable by H/E 
? origin from progenitor/stem cell or dedifferentiation 
from mature hepatocytes; increased likelihood recurrence, 
resistance to treatment, mets
 ● Uncommon; combined HCC-ChC; can be detected by HE and 
confirmed with IHC:HC component by HepPar, pCEA, CD10; 
ChC by K7, K19; mucin for mature biliary component; may 
have intermediate components at interface: K7, 19, CD56, c-kit, 
EpCAM (derivation from stem/progenitor; px is poorer than 
usual progressed HCC
 ● Rare; majority of tumor is stem/progenitor or intermediate; 
other names: hepatic stem cell; PLC of intermediate phenotype; 
cholangiolocellular [14,22–25]; Laennec society proposed 
name: mixed hepatobiliary carcinoma with stem/progenitor 
cell features
Px uncertain due to small numbers
Large-sized CLC had high recurrence








Woo et al. (2010) HCC, CC and combined HCC-CC By gene expression studies, distinct tumors but some HCC close 
to CC
[22]
Ikeda et al. (2013), (n = 36) Combined HCC-CC Added DLK-1 to IHC panel; separated cases into groups A and B 
according to < or >5% stem cells cases with >5% stem cells had 
worse prognosis; DLK-1 was usually pos in those cases
[26]
Akiba et al. (2013), (n = 54) Combined HCC-CC To confirm the classification of four subtypes of WHO, no effect of 
this classification
[27]
?: Questioned if tumor was of progenitor cell origin; CC: Cholangiocarcinoma; CLC: Cholangiolocellular carcinoma; HCC: Hepatocellular carcinoma;  
HCC-CC: Hepatocellular–cholangiocarcinoma; HPC: Hepatic progenitor cell; IHC: Immunohistochemistry; ISH: In situ hybridization; PLC: Primary liver carcinoma.
Table 1. Literature review on biphenotypic (hepatobiliary) primary liver carcinomas (cont.).
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CC [6–7,29–37] to yield prognostic information. 
It has since been shown that approximately 
25–30% of HCC diagnosed by histology show 
an expression of biliary markers, such as K7 
and/or K19 and this has been correlated to a 
worse prognosis [7,13,16–18,38]. Furthermore, in a 
study from 2002, Tickoo et al. investigated 27 
mixed tumors with IHC for biliary markers and 
with in situ hybridization for albumin mRNA, 
a specific marker for hepatocyte differentia-
tion [10]. A positive albumin signal was found in 
96% of PLCs and the authors concluded in favor 
of a biphenotypic differentiation.
Because of these results and the developing 
evidence for the existence of human hepato-
biliary stem cells during the same era [39–42], 
the idea of a stem/progenitor cell origin for 
b(HB)-PLC gained increasing traction. The 
first direct evidence of this possibility was in 
a collection of four cases of cHCC-CC ‘with 
stem cell features.’ [11]. In all four cases, there 
were populations of small cells, with high 
nuclear:cytoplasmic ratio, dense nuclear chro-
matin, arrayed around nests of hepatocytic 
and/or cholangiocytic cells. In all of these cases 
cells of intermediate morphology lay between 
these stem cell-like components and the more 
differentiated components, suggesting a visible 
maturation lineage.
Furthermore, different authors using different 
immunomarkers such as K19, K14 (cluster of 
differentiation) CD117/c-kit or EpCAM (epi-
thelial cell adhesion molecule) identified pro-
genitor cell expression in b(HB)-PLC and/or in 
otherwise typical HCC [8,13–14,16,23–24,36]. It was 
postulated that HCC in which a subpopulation 
is found expressing K19 arise from progeni-
tor cells [16,25] or result from dedifferentiation 
or transdifferentiation of tumoral hepatocytes 
yielding expression of ‘stemness’ features. This 
characteristic has always been associated with a 
worse prognosis [13,22].
Studies in the past decade undertaken to 
search for a relationship between b(HB)-PLC 
and classical CC or HCC have shown contra-
dictory results, probably related to the differing 
terminology as well as diagnostic criteria used 
by the different investigators [12,15,22,43–44]. 
Moreover, the spectrum of b(HB)-PLC was 
expanded with reports of new histological fea-
tures, associated with progenitor cell IHC mark-
ers. An example is the most recently proposed 
tumor. In 2001, Shiota et al., [45] reported a series 
of cholangiolocellular carcinoma (CLC), a par-
ticular type of PLC that had been described ini-
tially by Steiner in 1959 [4], but only by routine 
histochemical evaluation. CLC are usually [19], 
but not always [46] associated with HCC in con-
tinuity or elsewhere within the liver. These may 
or may not also contain overt CC. The charac-
teristic histologic feature is anastomosing regu-
lar ductules without lumina resembling canals 
of Hering in a dense, sclerotic stroma in which 
the epithelial component resembles the benign 
counterpart, that is, the ductular reaction [33]. In 
fact, this appearance itself led Shiota et al. [45] to 
consider a possible stem cell origin for the tumor. 
Detailed studies by Komuta et al. in a study of 
30 cases of CLC by morphology (both light 
and electron microscopy), IHC and molecular 
biology strongly support a stem/progenitor cell 
origin for CLC [19].
Table 2. Descriptive versus wHO classification of primary (mixed hepatobiliary) liver 
carcinomas.
Descriptive classification 2010 wHO classification
Stem cell/biliary marker positive (particularly K19+) 
‘pure’ HCC
HCC
HCC, small cell subtype HCC
HCC with stem cell features and IHC markers Unclassified
Hepatocyte marker positive pure CC Unclassified
cHCC-CC cHCC-CC
cHCC-CC with ‘typical’ stem cell features cHCC-CC, typical stem cell subtype
cHCC-CC with ‘intermediate’ features cHCC-CC, intermediate stem cell subtype
Cholangiolocellular carcinomas with HCC 
component
Unclassified
Cholangiolocellular carcinomas with cHCC-CC cHCC-CC, cholangiolocellular subtype
Primary liver carcinoma with mixed hepatobiliary 
IHC features (non-HCC, non-CC)
Unclassified
CC: Cholangiocarcinoma; cHCC-CC: Combined hepatocellular–cholangiocarcinoma; IHC: Immunohistochemistry.
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As a consequence of such IHC studies, crite-
ria to accurately diagnose b(HB)-PLC became 
confused. Are morphologically pure HCC or 
CC that display immunophenotypes of either 
stem, progenitor or mature epithelial cells of the 
‘other’ cell type actually a different tumor class? 
Or are they merely a subclass of the pure tumors 
with different prognostic markers (similar to the 
prognostic markers in clinical breast oncology)? 
Do overt histologic ‘stem cell features’ have clini-
cal significance that warrants a separate diagnos-
tic category? Furthermore, if stem cell features 
are only apparent by immunostains, should 
these be considered ‘stem cell tumors’? These 
and other important questions that arise from 
them are undergoing investigation, but currently 
there are no consensus answers.
The clinical impact of these reports led to 
a revision of the classification of such tumors 
by the WHO in the 2010 publication [20]. In 
this publication, for the first time, there is an 
entirely separate chapter to explore b(HB)-PLC 
(therein referred to as ‘combined hepatocellular–
cholangiocarcinoma’). This redefinition is pre-
liminary, inherently reflecting our early, incom-
plete understanding and describes two different 
forms: the classical cHCC-CC containing his-
tologically typical areas of HCC together with 
those of CC within the same tumor; and the 
cHCC-CC with stem cell features. In the WHO 
2010 chapter, this latter subtype is further 
divided into three categories: typical (nests of 
mature hepatocyte-like tumor cells surrounded 
by small cells exhibiting IHC markers of pro-
genitor cells), intermediate (small homogene-
ous tumor cells comprising most of the tumor 
that are intermediate between hepatocytes and 
cholangiocytes and showing IHC markers of 
both) and CLC [20]. In all of these groups, the 
histologic assessment is diagnostic, with IHC 
playing only a supportive, confirmatory role in 
tumor classification.
The revised WHO classification was utilized 
recently by Akiba et al. [27] in a study of 54 cases; 
the authors underlined the complexity of the 
histological features in b(HB)-PLC named and 
classified according to the 2010 WHO guide-
lines (i.e., cHCC-CC with or without stem 
cell features) and the difficulties in its appli-
cation, as only 1 of the 54 cases fit criteria of 
‘typical.’ The difficulty was also emphasized by 
the study of Ikeda et al. [26] who recommended 
evaluating the amount of stem cell features (as 
a percentage) in order to predict the prognosis. 
Sasaki et al. [47] also highlighted the variability of 
stem cell features in any given b(HB)-PLC, but 
also pointed out that different ‘stem cell feature’ 
subtypes were often present in the same tumor 
and, moreover, could be identified in many clas-
sical HCC with careful attention. Significant 
clinicopathologic associations were found with 
the presence of stem cell features [47].
b(HB)-PLC are frequent in cases of preexist-
ing liver disease, especially HCV and advanced 
fibrosis [33,48]. These tumors have also been 
reported in persistent or recurrent tumors after 
transarterial chemoembolization. This outcome 
of treatment in some cases may potentially 
impact the prognosis of patients after liver trans-
plantation [49,50] and raises again the question 
of transdifferentiation versus stem/progenitor 
cell origin. However, in clinical practice, these 
tumors are being noted with increasing fre-
quency in nondiseased liver as well [EM Brunt, 
Unpublished Data].
Importantly, new, cutting edge work by 
Holczbauer et al. [51] confirms that human 
HCC cell lines showing hepatocytic features can 
change genetic programming to become cancer 
stem cells with bipotent hepatobiliary differen-
tiative potential. As Zucmann-Rossi and Nault 
pointed out in an accompanying editorial [52], 
this work confirms that PLC may variously 
derive from malignant transformation of adult 
hepatocytes, liver stem/progenitor cells and fetal 
hepatoblasts, all of which can give rise to the 
mature-appearing cells of these tumors as well 
as to cancer stem cells within them that sustain 
tumor self-renewal and resistance to treatment. 
Raggi et al. [53] have further established that 
DNA methylation is a key epigenetic regulatory 
mechanism determining the pool of PLC cancer 
stem cells.
Histologic & immunophenotypic diversity 
of b(HB)-PLC
Leaving aside variations of straightforward 
‘pure’ (i.e., typical) HCC and pure CC, which 
are not reviewed, we summarize the histologic 
and immunophenotypic features of the various 
forms of b(HB)-PLC reported to date (Table 2). 
Two ‘broad’ groups of tumors show a mixture of 
biphenotypic (mixed hepatobiliary) phenotypes 
expressed at either the tissue or cellular levels.
 ● Tumors with biphenotypic/mixed hepatobil-
iary features at the tissue level show co-min-
gling of malignancies of the two different 
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cytologic and architectural features of HCC 
and CC, sometimes with cells of intermediate 
cytology/immunophenotype between them. 
These are commonly recognizable by light 
microscopy.
 ● Tumors with biphenotypic/mixed hepatobil-
iary features at the cellular level are not often 
recognized as such by light microscopy. These 
are largely monomorphic, and may be of var-
ying differentiation with or without a stromal 
component. However, with use of IHC, these 
tumors display mixed immunophenotypes 
either focally or diffusely within the tumor. 
These may be ‘traditional’ HCC or CC with 
immunostaining for markers of the other cell 
type or monomorphic tumors that cannot be 
classified histologically as either type, but in 
which immunophenotypic evidence is dem-
onstrated for combined hepatobiliary features 
at the cellular level.
Figure 1 is a schema to organize our knowledge 
of PLC. The areas denoted within each segment 
are not intended to reflect prevalence or inci-
dence of each type within the clinical spectrum 
of PLC, although obviously straightforward 
HCC and CC are the most common. The sche-
matic is meant as a device for organizing our 
knowledge of these tumors and as a stepping 
stone toward development of a robust, clinically 
relevant nomenclature.
Immunomarkers that are commonly used 
or that have been used in research efforts will 
also be discussed in each section. A variety of 
hepatocyte markers, cholangiocyte markers 
and stem cell markers are recognized, some of 
which are common in many clinical laborato-
ries, others of which are uncommon outside of 
research settings. These are collectively high-
lighted in Table 3. It is gratefully acknowledged 
that that this table was generated through 
Figure 1. Schematic diagram representing our present interpretation of primary liver carcinoma. 
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group discussion and with approval from the 
members of the 2013 meeting of the Laennec 
Hepatopathology Society held in Singapore 
(Aileen Wee, MD, USA host).
●● Pure HCC with biliary (stem cell) 
immunophenotype
Hepatocyte-like tumor with stem cell 
immunophenotype
Keratin 19 positive HCC is defined as a tumor 
with purely typical features of hepatocellular dif-
ferentiation and which expresses keratin 19 in 
≥5% of its cells; these cells are usually or mostly 
hepatocyte-like in morphology (Figure 2A & B). 
Such tumors (with the arbitrarily selected 5% cut 
off) have been shown to have a poorer prognosis 
with diminished disease free survival, increased 
likelihood of metastasis, greater chemoresist-
ance and diminished life expectancy [16,54]. 
Some have argued that this indicates that it 
should be treated as a separate, distinct subclass 
of HCC [36]; however, one can also argue that it 
should merely be considered a prognostic indi-
cator. The latter position is supported by the 
apparent emergence of keratin 19 expression or 
even overt cHCC-CC in recurrent HCC that 
previously had undergone ablative therapy [55]. 
Thus, rather than a distinct type of b(HB)-PLC, 
K19-positive HCC may perhaps better be con-
sidered in the spectrum of HCC itself. Future 
prospective clinical studies may be of value in 
further addressing these questions, keeping in 
mind that of the biliary markers K19 may also 
correlate with other marker expression of bil-
iary and/or stemness antigens such as CD56, 
EpCAM and CD133.
Isolated tumor cells with stem cell 
morphology confirmed by stem cell 
immunophenotype
Among the predominant hepatocyte-like cells 
in a pure HCC, are small, round to cuboidal, 
cells phenotypically similar to those of the 
canal of Hering in normal livers. Such stem 
cell-like tumor cells may be recognized by 
immunostaining for K19, CD56, EpCAM, 
CD133 and/or CD117/c-kit (at least). They are 
scattered individually or in clusters within the 
tumor (Figure 2C & D) or they may distribute along 
stromal boundaries either at the edges of the 
HCC or, more frequently along fibrous bands, 
within the tumor (Figure 2e & F) [11,55–56]. While 
the marker immunostaining is usually sharply 
defined and limited to these smaller cells, mor-
phology may reveal a pattern of cellular changes 
suggestive of a maturation lineage: from small, 
marker-positive, stem cell morphology to overt, 
marker-negative hepatocyte morphology. The 
frequent juxtaposition of the small cells against 
stroma is tempting to consider as a malignant 
variant of an hepatobiliary stem cell niche, com-
plete with cell:matrix localization that would 
potentiate interactions. The clinical implications 
of these stem cell-like findings, however, remain 
uncertain.
●● Pure CC with hepatocytic 
immunophenotype
The presence of some form of hepatocytic mark-
ers in CC has not been well studied. Hepatocyte 
in paraffin-1 (HepPar1) and arginase-1 have 
both been reported to be expressed in a minor-
ity of CC that are otherwise devoid of hepatocyte 
Table 3. immunohistochemical markers for evaluating differentiation in biphenotypic (hepatobiliary) primary liver carcinoma.
  Hepatocyte differentiation Biliary 
differentiation
Stem cell differentiation 
with stem cell morphology
Stem cell differentiation 
without stem cell 
morphology
Common markers 
(use as panel or use in 
sequence until a positive 
result is obtained)
HepPar1, Arginase-1,    
canalicular staining with 
Cd10, canalicular staining 
with pCeA, AFP 
Keratin 7, Keratin 
19, cytoplasmic 
staining for CeA 
(pCeA or mCeA), 
eMA (Muc-1)
Keratin 19, NCAM (Cd56), 
epCAM, eMA (Muc-1), c-kit 
(Cd117)





Nuclear staining for HNF4a Nuclear staining for 
sox-9
Nestin, Keratin 14, Cd133, 
nuclear staining for sox-9
Nuclear staining for oct-4 
Nuclear staining for Nanog 
Nuclear staining for sall-4
Bold text highlights the antibodies to be used.
For each differentiation state within a b(HB)-PLC – hepatocellular, biliary and stem cell – several markers are available; however, availability or cost may limit the utility of such large 
panels. On the other hand, lack of consistency between studies and/or centers can result in data that cannot be easily compared between different studies. To limit these 
difficulties, the panels in the upper row are recommended to be used either: as a panel with all antibodies applied to every case; or in a sequence, top to bottom, stopping with 
the first positive antibody. The markers in the bottom row are recognized as having utility for studying b(HB)-PLC, but are considered supplemental to the primary panels listed 
first. It is emphasized that morphology is primary in the assessment of subpopulations and immunophenotyping is secondary. In particular, stem cell components are assessed 
by routine light (H&E) microscopy before confirming by immunohistochemistry.
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Figure 2. ‘Pure’ hepatocellular carcinoma with 
biliary (stem cell) immunophenotype.  
(A & B) Hepatocyte-like tumor cells with stem 
cell immunophenotype: the features are those 
of hepatocellular differentiation with keratin 19 
expressed in ≥5% of the cells (in this case, 80%; 
hematoxylin and eosin [H&E] and K19, 15-times). 
(C & D) Hepatocyte-like tumor cells containing 
isolated tumor cells with stem cell morphology 
confirmed by stem cell immunophenotype, in 
this case, K19 (expressed in 5%; H&E and K19, 
10-times). (e & F) Hepatocyte-like tumor cells 
comprise the majority of the tumor, but tumor 
cells with stem cell morphology can be seen 
at (e) the stromal interface or (F) within the 
hepatocellular carcinoma (H&E, 10-times and 
15-times, respectively).
Biphenotypic (hepatobiliary) primary liver carcinomas Review
future science group www.futuremedicine.com
morphology [57,58]. There are no reports to sug-
gest that such hepatocytic expression indicates 
CC with better prognosis; clearly these are oth-
erwise typical CC in terms of their biology. It is 
also uncertain whether this should be taken as 
evidence of stem cell origin of some CC or redif-
ferentiation reflecting the flexible gene expres-
sion of non-neoplastic hepatobiliary lineages. It 
is worth noting, after all, that one may some-
times observe hepatocytes within non-neoplastic 
bile ducts.
●● cHCC-CC
By initial H&E evaluation, these tumors will 
show two intermixed cytologic/architectural 
patterns (Figures 3–5): areas suggestive of CC, 
for example, gland formation or strands of small 
cells with little cytoplasm or angulated ‘glands’ 
with poorly formed lumina, all of which usually 
occur in dense acellular stroma, and of HCC, 
that is, variably pleomorphic hepatocyte-like 
cells often with growth showing distortions 
of normal liver parenchyma, such as thick-
ened trabeculae or massively dilated canaliculi 
(‘pseudoglands’ or ‘pseudoacini’). The HCC 
component may have any of the common find-
ings in pure HCC, such as steatosis, ballooning 
with Mallory-Denk bodies and intercellular or 
intracellular bile accumulation.
Where the CC and HCC components meet 
the change may be abrupt or there may be transi-
tional cytologic, immunophenotypic or architec-
tural features. For example, there may be pseu-
doacinar formations lined not by hepatocytes, 
but by cuboidal, cholangiocyte-like cells, there 
may be what appear to be malignant variations 
of ductular reactions in which immunophe-
notyping demonstrates a lineage-like range 
of cytology and immunophenotypes ranging 
between cholangiocyte-like and hepatocyte-
like. These transitional areas may include not 
only the epithelial portions of the tumor, but 
also the amount and nature of the stroma; dense 
hyaline stroma readily characterizes many types 
of cholangio/cholangiolo/stem/progenitor cell 
carcinomas, These areas of dense hyalinized 
stroma may also include central areas of nearly 
‘empty’ stroma in which epithelial components 
are absent and only ghost-like spaces reminiscent 
of the structures remain.
By convention, fibrolamellar carcinoma is not 
considered such a tumor even though phenotypic 
markers that could be utilized to argue in favor 
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Figure 3. Biphenotypic (hepatobiliary) primary 
liver carcinoma. Immunohistochemistry 
highlights the mixed hepatobiliary nature 
of the tumor. (A) By hematoxylin and eosin 
stain, the tumor has an appearance of a 
monomorphic tumor both architecturally 
with cords and nests of tumor cells in a dense 
stroma, and cytologically with very little tumor 
cell pleomorphism (hematoxylin and eosin, 
15-times). (B) Immunohistochemical detection of 
HepPar-1 in scattered tumor cells highlights foci 
of tumor cells with hepatocyte differentiation 
(10-times). (C) Immunohistochemical detection 
of K19, a biliary or stem cell marker, is noted 
diffusely and uniformly strongly throughout the 
tumor (10-times).
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stroma are present [59]. It is excluded from consid-
eration in this group of tumors because neither 
the clinical presentation (typically in younger 
individuals and without association with chronic 
liver diseases) nor its clinical outcomes are similar 
to b(HB)-PLC being discussed herein. Likewise, 
the still rarer variant of scirrhous HCC, despite 
similar mixed immunophenotypes, is not 
included in this category [58].
●● cHCC-CC with stem cell features
This is a heterogeneous group of tumors that have 
been included in the current WHO tumor clas-
sification; however, that classification is imperfect 
in many respects, though it has served to raise 
interest in and stimulate research about these 
lesions and others described in this paper. Those 
with the most overtly stem cell-like features 
were the first ones described [11], and were thus 
designated ‘typical’ in the WHO classification, 
though subsequent series make it clear that these 
are uncommon at best [26–27,47]. What makes 
them so evocative is the presence of small stem 
cell-like cells that are contiguous with regions of 
HCC and with regions of CC, but also surround-
ing islands of well-differentiated hepatocytes 
without significant cytologic atypia, simulating 
a ductular reaction surrounding a cirrhotic nod-
ule, as though these presumably neoplastic cells 
are capable of giving rise to ‘normal’ hepatocytes. 
The striking appearance of these areas even with-
out any immunohistochemical staining is what 
drew attention to the lesions in the first place [11].
Additionally, there are cHCC-CC in which 
the majority of tumor cells show ‘intermediate’ 
morphology or what may appear to be ‘small 
hepatocytes’ [14]. The pattern may include tra-
beculae or elongated, ill-defined gland-like struc-
tures in dense stroma, but true gland formation 
with well-defined lumens and mucin production 
are absent. These cells stain for a combination of 
hepatocyte and cholangiocyte makers, and often 
for CD117/c-kit (Figure 6).
Though the current WHO classification 
includes this group of historically well-recog-
nized tumors as a stem cell subtype of cHCC-
CC, its relative frequency compared with those 
other types and its longstanding recognition as 
a separate category of tumor perhaps still merits 
it being separated as a distinct subtype. When 
the cholangiolocellular component predomi-
nates in the tumor, rather than as appearing as 
a small subtype within a larger, different tumor 
mass, this designation is warranted. Many of 
these, though not all, will have either a clear 
HCC component or a clear CC component or 





Figure 4. Biphenotypic (hepatobiliary) primary liver carcinoma. (A) By routine hematoxylin and 
eosin staining, it is apparent there are morphologic features of both hepatocellular carcinoma 
and cholangiocarcinoma in this tumor. The former is appreciated by trabeculae, and the latter by 
glands (hematoxylin and eosin 15-times). (B) Immunohistochemical reactivity of the glandular 
components is strong with K19; this stain also highlights the negative reactivity of much of the 
tumor (15-times). (C) Immunohistochemical detection of pCEA is in the canalicular components of 
the hepatocellular carcinoma, and lining of well-formed glandular components. No cytoplasmic 
reactivity is appreciated, as would have been expected in a cholangiocarcinoma (15-times). 
(D) Immunohistochemical detection of CD10 is similar to pCEA and is restricted to the canalicular 
components of the hepatocellular portions of the carcinoma (15-times).
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Figure 5.  Combined hepatocellular–cholangiocarcinoma. (A) By hematoxylin and eosin (H&E), 
there is an hepatocellular carcinoma (HCC) area showing hepatocyte-like tumor cells associated 
with tumor cells with stem cell morphology (H&E, 100-times). (B) A cholangiocarcinoma (CC) area 
shows cuboidal cells arranged in gland formation associated with an acellular fibrous stroma 
(H&E, 100-times). (C) This photomicrograph shows a transitional area with closely approximated, 
small homogeneous tumor cells intermediate between hepatocytes and cholangiocytes (H&E, 
100-times). (D) Immunohistochemical detection of glypican 3 is reactive in HCC area (200-times). 
(e) Immunohistochemical detection of K7 is reactive in CC area (200-times). (F) On macroscopic 
examination, this primary liver carcinoma appears relatively monomorphic, with features that are 
similar to CC than to HCC. These gross features include the white-tan color, firmness of the tumor and 
lack of obvious necrosis or bile. 
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that not all of these tumors, regardless of the 
recent WHO classification, are in fact cHCC-
CC. It is felt that the dominant, cholangiolocel-
lular compartment recapitulates features of the 
normative canal of Hering/ductule and perhaps 
the name should be limited to those tumors in 
which this compartment is well differentiated 
with minimal pleomorphism; cases in which 
higher grade, pleomorphic variants mimic this 
pattern are perhaps not the same entity. This 
bland tumor can be a ‘mimic’ of ductular reac-
tion [33] in cirrhotic septum on a small biopsy, 
but without the expected inflammation and 








Figure 6. Cholangiolocellular carcinoma. (A) This is a needle biopsy that illustrates the 
bland nature of the proliferative tumor cells in cholangiolocellular carcinoma. The tumor has 
the low power appearance of ductular reaction in cirrhotic septa, but the typical vascular 
proliferation and inflammation of septa are notably absent (hematoxylin and eosin four-times). 
(B) Immunohistochemical detection of HepPar1 shows occasional positivity in this small area of 
the tumor (20-times). (C) Immunohistochemical detection of K7 highlights the diffuse positivity 
of this marker of mature biliary cells and also shows the anastomosing nature of the tumor 
tubules (10-times). (D) Immunohistochemical detection of CD56 is also diffusely positive; this 
marker can be positive in a ductular reaction in certain types of reactive cases, as well as in certain 
cholangiolocellular carcinoma (10-times).
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●● PLC without typical morphology but with 
mixed hepatobiliary immunophenotype
These apparently novel PLCs which fit neither 
into the general categories of HCC, CC or cHCC-
CC have most dramatically made the case that a 
tripartite division of hepatobiliary malignancy is 
insufficient. These are tumors whose histomor-
phology differs from these three well-established 
PLCs, whose immunophenotypes often show 
considerable diversity both with heterogeneous 
staining for different hepatobiliary markers, but 
also including, occasionally, nonhepatobiliary 
antigens, for example, those associated with squa-
mous or endocrine or sarcomatous differentiation. 
Behavior of these tumors is not certain given that 
they are not in fact a uniform class, though the 
significant biliary features (either as overt CC, 
IHC expression of biliary/stemness markers or in 
behaviors such as perineural and lymphatic inva-
sion) suggest that their behavior will be likely 
more akin to CC than to HCC.
An example of such a tumor is shown in 
Figure 7. This figure should not be taken to be a 
new and specific tumor type; it is just one exam-
ple of a quite heterogeneous group of previously 
poorly recognized or described b(HB)-PLC. 
Indeed, whether these represent a ‘new’ kind of 
PLC or have been present, but only now being 
recognized, due new emphasis on stem/progeni-
tor cell interplay in hepatic neoplasia and more 
extensive immunostaining available globally, 
remains to be determined.
Molecular aspects of b(HB)-PLC
In recent years, molecular approaches dedicated 
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Figure 7. Primary liver carcinoma without typical morphology but with mixed hepatobiliary 
immunophenotype. (A & B) Hematoxylin and eosin photomicrographs illustrate small and large 
glandular-like formations with tumor cells of little pleomorphism, high N:C, vacuolated nuclei 
embedded within varying degrees of stroma (20-times). (C & D) Immunohistochemical detection of 
HepPar and CA19-9, respectively, show scattered reactivity, highlighting ‘biphenotypia’ (20-times). 
(e & F) Immunohistochemical detection of K19 and EpCam, respectively highlight ‘stem-ness’ 
(20-times).
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insights into biological behavior and pathogen-
esis, in both benign and malignant hepatocellular 
tumors. Whether morphological heterogeneity, a 
critical hallmark of b(HB)-PLC as emphasized 
above, reflects molecular heterogeneity has not 
been specifically addressed. Molecular studies 
focusing on such complex tumors would ideally 
include the preliminary step of tumor microdis-
section, in order to obtain gene expression profiles 
according to the different, distinct morphologic 
patterns. Nevertheless, based on the few stud-
ies of a relative low number of b(HB)-PLC, the 
following relevant information is known to date.
●● b(HB)-PLC: a clonal tumor
HCC and CC areas from a series of 11 b(HB)-
PLC were subjected to laser microdissection 
for clonal analysis by studying allelic status of 
a number of selected chromosomes’ arms [60]. 
Unexpectedly, loss of heterozygosity (LOH) at 
multiple chromosomal loci were identified in 
all tumors with three different LOH patterns, 
including biclonal neoplasms in three cases, 
consistent with the previously so-called col-
lision tumors, and single clonal neoplasms in 
eight cases, including four with homogeneous 
genetic changes and four with genetic diver-
gence. The common allelic losses shared by both 
tumor components were strongly suggestive of 
a single clonal derivation. Although performed 
on a limited number of cases, these clonal data 
are critically relevant, highlighting the relative 
discordance between morphologic heterogeneity 
and molecular homogeneity.
●● Molecular overlap of b(HB)-PLC with 
cholangiocarcinoma
There are several studies of chromosomal 
changes and gene expression patterns in b(HB)-
PLC. To note, none have included a preliminary 
tumor microdissection step. Thus, a series of 15 
b(HB)-PLC (specifically typical cHCC-CC) was 
screened for LOH using 400 microsatellite mark-
ers, p53 and b-catenin mutations and compared 
with three collision tumors, nine CC and a set 
of 137 HCC [15]. A high level of chromosome 
instability was found in both CC and cHCC-CC 
with recurrent specific LOH identified at 3p and 
14q, more frequently observed in both CC and 
cHCC-CC compared with HCC. According to 
these results, the authors suggested that cHCC-
CC is genetically closer to CC than HCC. This 
was further confirmed in a recent study, aiming 
to investigate the molecular pathways associated 
with pathogenesis of CLC. To address this issue, 
a genome wide transcriptional analysis was per-
formed in a set of 20 CLC [43]. The comparative 
analysis with CC and HCC demonstrated that 
CLC clustered with CC by hierarchical analysis 
while HCC and normal liver samples clustered 
together and CLC displayed biliary differentiation 
gene signature in parallel with downregulation 
of the hepatocyte differentiation program. These 
data are consistent with previous immunopheno-
typical analysis performed in a set of 30 CLC. As 
noted above, in this series, all cases had HCC-like 
areas, while 63% had CC-like areas. Strong posi-
tivity of mature cholangiocytic markers (K7 and 
K19) was present in all cases in both cholangio-
locellular areas and areas of overt CC, when pre-
sent, while hepatocellular markers (HepPar1 and 
canalicular staining with anti-CD10 and pCEA 
antibodies) were positive in HCC-like areas [19].
●● Molecular pathways involved in b(HB)-PLC
Notably, TGF-b-signaling pathway has shown to 
be specifically deregulated in CLC, with a signif-
icant number of upregulated fibrosis-associated 
genes, including genes encoding profibrogenic 
cytokines, extracellular matrix components and 
remodeling enzymes [43]. Such molecular fea-
tures might be expected in CLC which is usually 
rich in stroma. Whether a similar extracellular 
matrix signature could be a common feature 
of other b(HB)-PLC subtypes certainly merits 
investigation. Interestingly, increase in TGF-b-
signaling pathway expression, including TGF-b, 
TGFbR1 and Smad4, has also been reported in 
a subset of HCC characterized by the presence 
of prominent fibrous stroma, namely ‘scirrhous 
HCC’ [61]. In addition, scirrhous HCC displayed 
a CC-like gene expression trait that could be 
at least partly attributed to the presence of the 
tumoral fibrous stroma [61].
●● Nomenclature & research methodologies
The 2010 WHO designation of cHCC-CC with 
and without stem cell features, and the three 
subtypes of ‘cHCC-CC with stem cell features,’ 
has several organizational benefits: defining and 
cataloging some of the diversity of b(HB)-PLC, 
recognizing that the CLC is likely a progenitor 
cell carcinoma with poor clinical behavior and 
‘grouping’ of otherwise disparate primary tumors 
within the liver by immunophenotype and poor 
clinical outcomes. However, the attempted brev-
ity reflected by these subtypes does not, in fact, 
encompass all that one encounters either in 
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practice or in experimental settings. The pre-
viously referenced study by Akiba et al. [27] of 
b(HB)-PLC has shown the challenges of utiliz-
ing this WHO classification. While the careful 
delineation of the subgroups by IHC analysis 
documented the rarity of the typical subtype 
compared with intermediate and cholangiolocel-
lular subtypes, the categorization led to no signifi-
cant differences in clinical outcomes between the 
groups or subgroups. Furthermore, the authors 
noted that while confirmation of progenitor cell 
phenotype could be made by their study, the spec-
tra of histology was still not entirely met by the 
WHO criteria and more work would be beneficial 
to further understand these tumors. The study by 
Sasaki et al. [47] further emphasizes these prob-
lems by showing that many b(HB)-PLC display 
more than one subtype of stem cell features.
Thus, it is clear that for further, efficient devel-
opment of a rational, clinically useful classifica-
tion scheme for b(HB)-PLC, a uniform approach 
to study would be of benefit. At a recent meeting 
of attending members (see Acknowledgements) 
of the Laennec Hepatopathology Society 2013 
Meeting held in Singapore consensus regard-
ing nomenclature was judged premature, but a 
proposed consensus regarding efficient research 
standards was achieved. These recommendations 
were:
 ● Multiple areas of each tumor deserves evalua-
tion in order to be appropriately classified, 
based on:
 ū Radiologic evaluation and subsequent careful 
radiologic-gross pathologic correlation at the 
bench, or
 ū Sampling of grossly different areas of tumor at 
the time of gross description or
 ū Laser capture microdissection from slides.
 ● Identification of subpopulations within a tumor 
begins with morphologic assessment for hepat-
ocyte-like (large cells, arrayed in pseudoglands, 
thickened trabeculae or round, tubular struc-
tures, surrounded by CD34+ endothelium); 
cholangiocyte-like (forming glands, with or 
without mucin production) and stem-like 
(small cells round, oval or cuboidal cells with 
high nuclear:cytoplasmic ratio, hyperchromatic 
nuclei).
 ● Immunophenotypic evaluation follows with 
standardization of immunohistochemical 
markers for hepatocellular, cholangiocellular 
and stem/progenitor cell differentiation 
(Table 3). To promote uniformity of approach 
between research laboratories and to foster data 
sets that can be easily compared across geo-
graphic and institutional boundaries these 
antibodies are listed, and ranked in a proposed 
sequence of use. Thus, the markers within a 
group may all be utilized at the same time or 
utilized sequentially until one is positive. If all 
are completed and none is positive, the recom-
mendation is to move to the next set. One 
deviation from the above ‘morphology before 
immunophenotype’ proposal is the cautious, 
provisional recognition that any morphology 
with positive nuclear Oct 3/4, Sox 2, Nanog 
or Sall4 would also represent a stem cell immu-
nophenotype. The members also discussed and 
agreed that any other antibodies one chose to 
use in any of the above three categories are 
optional, including, for example, K14 and c-kit 
(CD117).
Conclusion
The identification and analysis of b(HB)-PLC 
raise many questions crucial for understanding 
minimum diagnostic criteria (clinically, radio-
logically and pathologically), prognostic assess-
ments, development of appropriate treatments 
and monitoring the possibly changing epidemi-
ology of PLC worldwide. These include (but are 
not limited to) the following questions:
 ● These tumors may be seen with and without 
chronic liver disease: are they becoming more 
common ? Or were they s imply 
‘underappreciated’ or ‘underevaluated’ in prior 
studies?
 ● If they are more common is this due to chang-
ing epidemiology of underlying chronic dis-
eases (e.g., the denouement of HCV disease 
and, subsequently, increased prevalence and 
incidence of malignancy in NAFLD)? Could 
the increasingly common setting of post-treat-
ment, but unremitted liver disease be creating 
a new tumor environment in which b(HB)-
PLC are more likely to emerge (e.g., patients 
with unsuccessful antiviral regimens)? Is the 
increasing prevalence of mixed diseases 
(e.g., viral hepatitis and NAFLD, mixed viral 
infections) related to b(HB)-PLC development?
 ● How much (if at all) do the clinical features and 
natural histories of these different kinds of 
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b(HB)-PLC differ from their single phenotype, 
‘classic’ counterparts? Are stem cell features a 
curiosity only relevant for understanding hepa-
tocarcinogenesis or do they have true prognostic 
and/or treatment implications?
 ● Given the heterogeneity within b(HB)-PLC 
what is sufficient tumor sampling? Is single nee-
dle core sampling of tumors with suspiciously 
varied radiographic appearance sufficient? Or 
do separate biopsy specimens need to be 
obtained from areas with different radiologic 
appearances?
 ● What are the minimal criteria for including 
immunostains for subclassification? Further, 
what will be the role for the more sophisticated 
molecular studies that are becoming increasingly 
available?
 ● Does treatment of pure HCC sometimes lead 
to emergence of b(HB)-PLC or are recurrences 
of b(HB)-PLC post-treatment of a classical 
HCC evidence that it originally was, in fact, an 
undiagnosed b(HB)-PLC, prior to treatment? 
Or are both pathways for post-treatment tumor 
appearance possible?
 ● What is the post-treatment history of different 
types of b(HB)-PLC?
The literature cited and observations described 
in this review as well as the attempts to answer 
questions such as those above will vastly extend 
our knowledge of the biology of hepatocarcino-
genesis. In terms of clinical practice, however, the 
growing acceptance of b(HB)-PLC poses major 
challenges to all professionals involved in the care 
of patients with liver cancer: imaging and interven-
tional radiology colleagues, clinical oncologists, 
liver surgeons and transplant surgeons as the ‘natu-
ral history’ of this tumor phenotype is still being 
actively studied. As demonstrated, these tumors 
are certainly challenging for pathologists in terms 
of histological diagnosis and nomenclature.
Future perspective
We are continuing and also at the beginning 
of a fascinating journey for all those clinicians 
and scientists interested in cancers that arise in 
the liver. It is exciting to recognize that all of 
our eventual progress will come from extensive 
interdisciplinary and multi-institutional research 
efforts. In the coming years we can look forward 
to greater understanding as to the histogenesis 
and pathobiology that lead to these complex 
forms of hepatobiliary malignancy. The first 
achievement will be a consensus terminology to 
describe these tumors to facilitate all subsequent 
work. As tumors are better classified according 
to consistent clinical and histological features, 
the most important molecular (genetic and 
epigenetic) features of the tumors will emerge. 
Such information, through interdisciplinary 
collaborations with molecular biologists, diag-
nostic and interventional radiologists, hepatol-
ogists and pathologists will lead to improved, 
more sensitive and specific screening protocols 
for early detection. Our ultimate expectation 
is that targeted therapies specific to individual, 
histologically characterized and (epi-) geneti-
cally defined subcomponents within a patient’s 
tumor may result in improved, tailored thera-
pies. Furthermore, these protocols may also be 
tailored to the specific background chronic liver 
diseases in which most of these tumors arise.
The authors acknowledge that we are sim-
ply four academic liver pathologists of a larger 
community. We invite all our liver colleagues, 
in pathology and other diverse, but related clini-
cal and scientific fields, to join us for what is 
proving to be an exciting intellectual adventure. 
Inevitably, together, we will produce significant 
advances in patient care and further insights into 
hepatobiliary carcinogenesis.
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